001     177230
005     20240229133734.0
024 7 _ |a 10.1016/j.ijrobp.2021.07.829
|2 doi
024 7 _ |a pmid:34701007
|2 pmid
024 7 _ |a 0360-3016
|2 ISSN
024 7 _ |a 1879-355X
|2 ISSN
037 _ _ |a DKFZ-2021-02364
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Liew, Hans
|0 P:(DE-He78)dc4247d1e899d0fd333732064f422a0f
|b 0
|e First author
|u dkfz
245 _ _ |a Combined DNA Damage Repair Inhibition and Ion Beam Therapy: Development, Benchmark and Clinical Implications of a Mechanistic Biological Model.
260 _ _ |a Amsterdam [u.a.]
|c 2021
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1650981245_16147
|2 PUB:(DE-HGF)
|x Other
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #EA:E050# Abstract
520 _ _ |a Cellular radiosensitivity is tightly linked to DNA damage repair (DDR) capability. In a clinical context, inhibition of key DDR enzymes within tumor results in improved tumor control after radiotherapy and many preclinical and clinical trials of radiosensitizing drugs targeting DDR enzymes have been recently conducted or launched. Concurrently, interest in ion beam therapy continues to grow globally and its high precision may provide ideal treatment attributes in combination with tumor radiosensitizers. However, most studies of tumor radiosensitization based on DDR inhibition have been or are conducted using prevalent photon beams. Here, a mechanistic model of biological radiation response is presented to accurately translate findings in DDR inhibition studies to the case of charged particle radiation.The mechanistic 'UNIfied and VErsatile bio-response Engine' (UNIVERSE) and its model of radiosensitization by DDR inhibition is extended to charged particles by implementing the heterogeneous dose distributions of protons and helium ions utilizing GPU computation. Predictions for monoenergetic and mixed fields over clinically relevant dose and LET range are compared to cell survival data from the literature and own dedicated experiments, including different cell lines and DDR inhibited variants. Our own experimental data represents the first comprehensive measurement of cell survival of repair competent and deficient cell lines in a helium spread-out bragg peak. Ultimately, the predictions of UNIVERSE are considered in a concrete clinical situation based on patient plan recalculations.UNIVERSE is able to precisely predict cell survival of DDR competent and deficient cell lines in clinically relevant settings of ion beam therapy based only on up to 3 parameters derived solely from conventional photon data. With increasing LET the effect of DDR deficiency reduces. This results in a diminished RBE of ion beam radiation for DDR deficient cells in comparison to DDR proficient cells.The capabilities of UNIVERSE could lead towards more personalized and 'biological' planning in charged particle therapy, that could be guided by bio-marker based imaging in the future. By increasing the coverage of a tumor with high-LET using modifications of the treatment planning optimizer or advanced irradiation techniques, one could exploit the reduced impact of DDR inhibition at high LET to reduce the adverse effects of heterogeneous tumor radiosensitivity. UNIVERSE could also aid the appraisal of clinical viability of combined administration of radiosensitizing drugs and charged particle therapy and the identification of patients with known DDR inhibition which might not benefit from ion beam therapy, facilitating the management of limited capacities at therapy centers.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
700 1 _ |a Meister, Sarah
|0 P:(DE-He78)df14a88d357c289b53f2561141bd9ca9
|b 1
|u dkfz
700 1 _ |a Mein, S.
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Kopp, B.
|0 P:(DE-He78)32565894b8bfbe22e80198849cca18a2
|b 3
|u dkfz
700 1 _ |a Abdollahi, A.
|0 P:(DE-He78)360c5bc2b71a849e35aca747c041dda7
|b 4
|u dkfz
700 1 _ |a Debus, J.
|0 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
|b 5
|u dkfz
700 1 _ |a Dokic, I.
|0 P:(DE-He78)e24b607ded082a3089a1f6bf326a7a8e
|b 6
|u dkfz
700 1 _ |a Mairani, A.
|b 7
773 _ _ |a 10.1016/j.ijrobp.2021.07.829
|g Vol. 111, no. 3S, p. e247 - e248
|0 PERI:(DE-600)1500486-7
|n 3S
|p e247 - e248
|t International journal of radiation oncology, biology, physics
|v 111
|y 2021
|x 0360-3016
909 C O |p VDB
|o oai:inrepo02.dkfz.de:177230
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)dc4247d1e899d0fd333732064f422a0f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)df14a88d357c289b53f2561141bd9ca9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)32565894b8bfbe22e80198849cca18a2
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)360c5bc2b71a849e35aca747c041dda7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)8714da4e45acfa36ce87c291443a9218
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)e24b607ded082a3089a1f6bf326a7a8e
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-01-27
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-27
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b INT J RADIAT ONCOL : 2019
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-27
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-27
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b INT J RADIAT ONCOL : 2019
|d 2021-01-27
920 1 _ |0 I:(DE-He78)E050-20160331
|k E050
|l E050 KKE Strahlentherapie
|x 0
920 1 _ |0 I:(DE-He78)HD01-20160331
|k HD01
|l DKTK HD zentral
|x 1
920 1 _ |0 I:(DE-He78)E210-20160331
|k E210
|l E210 Translationale Radioonkologie
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E050-20160331
980 _ _ |a I:(DE-He78)HD01-20160331
980 _ _ |a I:(DE-He78)E210-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21